文献速递泌尿男性生殖肿瘤

TAR-200用于卡介苗无反应高危非肌层浸润性膀胱癌:IIb期SunRISe-1研究结果

TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
PubMed 文献 · J Clin Oncol · 2025-07-30

SunRISe-1是一项IIb期平行队列研究,评估TAR-200单药或联合西利单抗(cetrelimab)在卡介苗无反应高危非肌层浸润性膀胱癌中的疗效。TAR-200单药在原位癌队列的完全缓解率为82.4%,在乳头状病变队列的12个月无病生存率为70.2%,且耐受性良好。

要点

  • TAR-200单药治疗卡介苗无反应原位癌的完全缓解率为82.4%,中位缓解持续时间25.8个月。
  • TAR-200单药治疗乳头状病变的6、9、12个月无病生存率分别为85.3%、81.1%、70.2%。
  • TAR-200单药≥3级治疗相关不良事件发生率为12.9%,未发生治疗相关死亡。

核心结论

  • TAR-200单药耐受性良好,在卡介苗无反应高危非肌层浸润性膀胱癌中具有高完全缓解率、持久缓解和延长无病生存。
  • 在卡介苗无反应原位癌中,TAR-200单药的风险获益特征优于TAR-200联合西利单抗或西利单抗单药。

研究设计与样本

  • IIb期平行队列研究,纳入卡介苗无反应原位癌伴或不伴乳头状病变患者接受TAR-200单药(队列2)、TAR-200联合西利单抗(队列1)或西利单抗单药(队列3),卡介苗无反应高危乳头状病变患者接受TAR-200单药(队列4)。
  • TAR-200给药至第24个月,西利单抗给药至第18个月。
  • 主要终点为中心确认的总体完全缓解率(队列1-3)或无病生存率(队列4),临床试验注册号NCT04640623。
  • 截至2025年3月31日数据截止,队列1-4分别有53、85、28和52例患者接受治疗。

主要发现

  • 队列2的完全缓解率为82.4%(95% CI,72.6至89.8),中位缓解持续时间为25.8个月(95% CI,8.3至不可估计)。
  • 队列4的6、9、12个月无病生存率分别为85.3%(95% CI,71.6至92.7)、81.1%(95% CI,66.7至89.7)和70.2%(95% CI,51.6至82.8)。
  • 队列1和队列3的完全缓解率分别为67.9%(95% CI,53.7至80.1)和46.4%(95% CI,27.5至66.1)。
  • 队列2、4、1、3的≥3级治疗相关不良事件发生率分别为12.9%、13.5%、37.7%和7.1%,严重治疗相关不良事件发生率分别为5.9%、5.8%、15.1%和3.6%。
  • 未发生治疗相关死亡。

关键数值与推荐

  • 队列2(TAR-200单药,原位癌)完全缓解率82.4%(95% CI,72.6至89.8)。
  • 队列1(TAR-200联合西利单抗,原位癌)完全缓解率67.9%(95% CI,53.7至80.1)。
  • 队列3(西利单抗单药,原位癌)完全缓解率46.4%(95% CI,27.5至66.1)。
  • 队列4(TAR-200单药,乳头状病变)12个月无病生存率70.2%(95% CI,51.6至82.8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: TAR-200 is a first-in-class intravesical drug-releasing system designed to provide sustained delivery of gemcitabine in the bladder. TAR-200 alone or in combination with cetrelimab (PD-1 inhibitor) could improve outcomes in patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) ineligible for or refusing radical cystectomy. METHODS: In this phase IIb parallel cohort study, patients with BCG-unresponsive carcinoma in situ (CIS) with/without papillary disease received TAR-200 monotherapy (Cohort 2 [C2]), TAR-200 plus cetrelimab (C1), or cetrelimab monotherapy (C3). Patients with BCG-unresponsive high-risk papillary disease-only NMIBC received TAR-200 monotherapy (C4). TAR-200 was dosed through month 24 and cetrelimab through month 18. Primary end points were centrally confirmed overall complete response (CR) rate (C1-3) or disease-free survival (DFS) rate (C4) (ClinicalTrials.gov number: NCT04640623). RESULTS: At data cutoff (March 31, 2025), 53, 85, 28, and 52 patients were treated in C1-4, respectively. In C2, CR rate and median duration of response were 82.4% (95% CI, 72.6 to 89.8) and 25.8 months (95% CI, 8.3 to not estimable), respectively. In C4, 6-, 9-, and 12-month DFS rates were 85.3% (95% CI, 71.6 to 92.7), 81.1% (95% CI, 66.7 to 89.7), and 70.2% (95% CI, 51.6 to 82.8), respectively. In C1 and C3, CR rates were 67.9% (95% CI, 53.7 to 80.1) and 46.4% (95% CI, 27.5 to 66.1), respectively. Rates of grade ≥3 treatment-related adverse events (AEs) were 12.9%, 13.5%, 37.7%, and 7.1% in C2, C4, C1, and C3, respectively, and of serious treatment-related AEs, 5.9%, 5.8%, 15.1%, and 3.6%. No treatment-related deaths occurred. CONCLUSION: TAR-200 monotherapy was well tolerated, with a high CR rate, durable responses, and prolonged DFS in patients with BCG-unresponsive high-risk NMIBC. TAR-200 monotherapy offered a more favorable risk-benefit profile versus TAR-200 plus cetrelimab or cetrelimab alone in BCG-unresponsive CIS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Daneshmand S, Van der Heijden MS, Jacob JM, et al. TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. J Clin Oncol. 2025. PMID: 40737582. doi:10.1200/JCO-25-01651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。